My watch list
my.bionity.com  
Login  

Roche Announces Thomas Schinecker as New President of 454 Life Sciences

18-Jul-2011: 454 Life Sciences, a center of excellence of Roche’s business unit Applied Science,  announced that effective August 1, 2011, Dr. Thomas Schinecker is appointed Lifecycle Leader for Sequencing and President of 454 Life Sciences, Inc., in Branford, Connecticut, USA, reporting to Robert Yates, Head of Applied Science.

Dr. Schinecker is currently the Diagnostics General Manager of Sweden, located in Bromma, a suburb of Stockholm.  Dr. Schinecker’s extensive background and experience of over eight years at Roche will be instrumental in guiding 454 Life Sciences into the next generation of pyrosequencing. Dr. Schinecker holds a PhD in oncology, studying at the New York University. He then excelled in several leadership positions in the Sales & Marketing organization of Roche Diagnostics Austria, starting his career at Roche in the Perspectives Program in 2003. With his success in several key management positions within Roche Diagnostics, Dr. Schinecker brings the required organizational and operating skills to 454 Life Sciences’ highly innovative and accurate long sequence read technology. 454 Sequencing Systems are used productively by large numbers of life science researchers in cancer, infectious disease, immunogenetics, drug discovery, agriculture and other disciplines, resulting in more than 1,000 peer-reviewed publications.

Facts, background information, dossiers
More about 454 Life Sciences
More about Roche
  • News

    Roche acquires Trophos

    Roche announced that it has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos’s proprietary screening platform generated olesoxime (TRO19622), which is being developed for SMA – a rare and debilitating genetic neuromuscular disease that is ... more

    WILEX subsidiary Heidelberg Pharma extends research collaboration with Roche

    WILEX AG announced that WILEX subsidiary Heidelberg Pharma and Roche extended the existing 2013 licence agreement to apply the antibody drug conjugate (ADC) technology for the further development of Roche antibodies. The aim is to identify and develop novel AntibodyTargeted Amanitin Conjuga ... more

    Roche purchases shares in tender offer for InterMune, Inc.

    Roche and InterMune, Inc. announced that Roche’s wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of InterMune, Inc. at USD 74.00 per share in cash. The tender of ... more

  • Companies

    Roche Austria GmbH

    Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche i ... more

    Roche Deutschland Holding GmbH

    more

More about Roche Diagnostics
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE